Is oral squamous cell carcinoma arising in the background of oral submucous fibrosis a distinct entity? A systematic review and meta-analysis of clinicopathological and prognostic outcomes.

Int J Oral Maxillofac SurgMay 21, 2026 (epub)
Clinical ResearchOncology (Medical)Otolaryngology (ENT)

A R Gadbail, M Yuwanati, M Chaudhary et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated clinicopathological and survival outcomes of oral squamous cell carcinoma (OSCC) arising in the context of oral submucous fibrosis (OSCC-OSMF) compared to non-OSMF-OSCC. The analysis included twelve observational studies, revealing that OSCC-OSMF patients had a 5-year overall survival rate of 2.35 times better than their non-OSMF counterparts.

Key findings

  • OSCC-OSMF patients were younger and predominantly male, with the buccal mucosa as the most common site.
  • OSCC-OSMF presented at earlier stages with an odds ratio of 2.19.
  • Nodal metastasis was significantly less common in OSCC-OSMF, with an odds ratio of 0.53.
  • The 5-year overall survival rate for OSCC-OSMF was 2.35 times better than for non-OSMF-OSCC.

Why it matters

Understanding the distinct characteristics of OSCC-OSMF can inform clinicians about its lower metastatic potential and better survival outcomes, which may influence surveillance strategies and treatment approaches.

Source

PubMed · PMID 42167964

Published in Int J Oral Maxillofac Surg. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.